Difference between revisions of "Murakami S, et al. Stem Cells (2015) cited as Ref 76 in DOI: 10.1038/s41392-020-0110-5 (Q9339)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 33, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): SRY and OCT4 are required for the acquisition of cancer stem cell-like properties and are potential differentiation therapy targets, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | SRY and OCT4 are required for the acquisition of cancer stem cell-like properties and are potential differentiation therapy targets (English) | ||
| Property / title: SRY and OCT4 are required for the acquisition of cancer stem cell-like properties and are potential differentiation therapy targets (English) / rank | |||
| + | Normal rank | ||
Revision as of 21:50, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Murakami S, et al. Stem Cells (2015) cited as Ref 76 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Murakami S
0 references
2015
0 references
Stem Cells
0 references
33
0 references
SRY and OCT4 are required for the acquisition of cancer stem cell-like properties and are potential differentiation therapy targets (English)
0 references
